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Available online 12 September 2013The use of placebo controls in clinical trials remains controversial. Ethical analysis and international
ethical guidance permit the use of placebo controls in randomized trials when scientifically
indicated in four cases: (1) when there is no proven effective treatment for the condition under
study; (2) when withholding treatment poses negligible risks to participants; (3) when there are
compelling methodological reasons for using placebo, and withholding treatment does not pose a
risk of serious harm to participants; and, more controversially, (4) when there are compelling
methodological reasons for using placebo, and the research is intended to develop interventions that
can be implemented in the population fromwhich trial participants are drawn, and the trial does not
require participants to forgo treatment theywould otherwise receive. The concept ofmethodological
reasons is essential to assessing the ethics of placebo controls in these controversial last two cases.
This article sets out key considerations relevant to consideringwhethermethodological reasons for a
placebo control are compelling.
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Randomized, placebo-controlled trials (PCTs) are widely
considered to be the most rigorous method of evaluating the
efficacy of treatment or prevention interventions. To be ethical,
clinical research requires balancing rigorous science with the
protection of human subjects. Most people accept the use of
placebo controls in trials for conditions with no effective
treatment. However, PCTs raise ethical concerns when a proven
effective treatment exists, since randomizing subjects to a
placebo exposes them to the potential harms of non-treatment
[1]. The choice of a PCT design over other designs, such as
active-controlled superiority or non-inferiority trials, therefore
requires ethical justification. In this paper, we review ethically
acceptable uses of placebo in randomized controlled trials andlinical Center, National
ethesda, MD 20892,
).
Inc.analyze how and when methodological reasons are compelling
enough to justify placebo use.
2. Permissible use of placebo
There are four cases in which a placebo control design, when
scientifically appropriate, is also considered ethically acceptable
(Table 1). First, PCTs are acceptable when there is no proven
effective intervention for the condition under study, or when
placebo is compared against an investigational treatment added
on to established treatment. This includes trials of treatments
shown to be efficacious in some populations but where the data
cannot be extrapolated to the population of interest. Use of
placebo in this case is typically not ethically controversial.
Second, placebo is acceptable “when withholding an es-
tablished, effective intervention would expose subjects to, at
most, temporary discomfort or delay in relief of symptoms,” as
noted in the Council of International Organizations of Medical
Sciences' (CIOMS) International Ethical Guidelines for Biomedical
Research Involving Human Subjects [2]. For example, it would be
acceptable to use a placebo in testing a treatment for allergic
Table 1
When is it permissible to use a placebo control?
Condition Variants Examples
1. No proven effective intervention for condition
under study.
No treatment exists.
Trial tests add-on treatment
Data on existing treatment cannot be
extrapolated to the population of interest.
Trial of a new medication to prevent Alzheimer's dementia
[23]
Trial of a new agent against placebo added to standard
chemotherapy for ovarian cancer [24]
Trial to test whether an existing anti-depressant is
efficacious in the treatment of PTSD [25]
2. No or negligible harms from delaying or
forgoing treatment.
Not treating is an acceptable option for
the condition under study.
Negative consequences of not receiving
treatment are negligible.
Trial of medication for male pattern baldness [26]
Trial of medication for symptom relief of allergic rhinitis
[27]
3. Compelling methodological reasons for use of
placebo; and
Participants are not at risk of excessive harm.
High expected placebo response
OR
Fluctuating outcomes
AND
Mixed data on effectiveness of standard
treatment
Trial of new analgesic [28]
Trial of new treatment for psoriatic arthritis [29]
Trial of new anti-depressant [30]
4. Compelling methodological reasons for use of
placebo; and
Participants are not deprived of interventions they
would otherwise receive; and
Research intended to develop interventions that
will benefit the host population.
Short course AZT for prevention of mother to child HIV
transmission [31]
Trial of rectal artesunate as initial treatment for severe
malaria patients en route
to referral clinics [32]
511J. Millum, C. Grady / Contemporary Clinical Trials 36 (2013) 510–514rhinitis, a common headache, or male pattern baldness.
In other words, placebo is permissible when the negative
consequences of going untreated are negligible or no treatment
is an acceptable alternative.
A third justification is sometimes invoked to justify
placebo controls in trials of new treatments for conditions
whose response to both established treatments and placebo
is highly variable [3]. For example, depression has fluctuat-
ing symptoms and a high placebo response rate. It is not
uncommon to have inconsistent evidence of the efficacy of
approved anti-depressants—showing superiority to placebo
on some endpoints in some trials but not others [4].
Demonstrating equivalence or non-inferiority of an investi-
gational compared to an approved anti-depressant treat-
ment may mean that the new drug is as efficacious as the
established anti-depressant or that neither the established
nor the investigational drug performed better than placebo in
this trial. Similar phenomena can arise with anti-psychotics,
treatments for mania, and analgesics. In such cases a placebo
control may be necessary in order to establish the efficacy of a
new treatment.
However, the fact that a placebo control is necessary to
demonstrate efficacy is not sufficient to justify it. Sometimes the
risks of forgoing treatment—for example, for a life-threatening
condition—are so high that it would not be ethical to ask
participants to accept them. Unlike for the previous justification,
the risks of forgoing or delaying treatment need not be
negligible. However, as with any research study, there are limits
to the level of risk to which participants may be exposed, risks
must be minimized, and risks must be justified by the value of
the expected knowledge. Accordingly, the CIOMS guidelines
permit placebo use:
When use of an established effective intervention as
comparator would not yield scientifically reliable results
and use of placebo would not add any risk of serious or
irreversible harm to the subjects [2].Likewise, the Declaration of Helsinki allows placebo controls:
Where for compelling and scientifically sound methodolog-
ical reasons the use of placebo is necessary to determine the
efficacy or safety of an intervention and the patients who
receive placebo or no treatment will not be subject to any
risk of serious or irreversible harm [5].
Finally, some guidelines permit PCTs under certain unusual
conditions in developing countries [6]. Sometimes an effective
treatment is not available to a population for economic or
logistic reasons. Researchers and policy makers may seek to
develop a less expensive or easier to administer treatment that
could be made available. They may expect that the newer
treatment will be less effective than the existing alternative, or
there may be reasonable doubts about extrapolating data from
other populations to the developing country patients. Compar-
ison to placebomay then be scientifically necessary to evaluate
the efficacy of the new intervention in that context.
This last justification was articulated for PCTs of “short
course” AZT for the prevention of mother to child HIV
transmission in developing countries in the late 1990s. An
intervention proven effective in the U.S. for reducing perinatal
transmission using Zidovudine (AZT), the “076 regimen,” had
become the standard of care in developed countries. Although
the original U.S. trial showed that AZT given intravenously
prenatally, during delivery, and postpartum reduced the HIV
transmission rate from mother to newborn by approximately
two-thirds, [7] it had little prospect of implementation in the
developing countries where the majority of perinatal HIV
infections occurred: they lacked necessary infrastructure, many
women did not receive prenatal care, and the drugs were too
expensive.
These trials were controversial. Critics argued that placebo
usewas unnecessary to test the efficacy of short course AZT and
that the trials represented an unethical “double standard” [8,9].
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course AZT might be less effective than the 076 regimen, an
active controlled trial would be uninformative regarding the
efficacy of short course AZT, and that there was a compelling
public health need for a cheaper, less complex intervention
[10].
This debate helped clarify conditions for ethically per-
missible PCTs in populations without access to existing
effective treatments. Such trials can be justified if: (1) the
research is intended to develop interventions to be
implemented in the population fromwhich trial participants
are drawn, (2) the trial does not require participants to forgo
treatment they would otherwise receive, and (3) there are
compelling methodological reasons for using a placebo
control [11].
3. Interpreting the justifications for placebo controls
Though debate continues, there is fairly widespread
agreement that using a placebo control in these four cases, or
something like them, can be ethically justifiable. However, how
to interpret the conditions under which they apply remains
unsettled, especially for the third and fourth cases.
First, there is no consensus regarding the level of risk to
which participants may be exposed by forgoing treatment. For
example, is exposing participants to the risk of a depression
relapse too great a risk? It is not adequate to proscribe placebo
use when it might lead to “any serious or irreversible harm,” as
CIOMS and the Declaration of Helsinki suggest. Not treating a
finger cut orminimal risk procedures like skin biopsies can lead
to irreversible scarring and carry a tiny chance of serious harm
from infection. Instead, it seems sensible to allow participants
to be exposed to the same degree of risk by forgoing treatment
that is allowable when they undergo other research proce-
dures. Interpretation of the risk condition for PCTs should
therefore be assimilated to the more general—albeit still
unsettled—question of what level of risks it is permissible to
ask informed people to take on in research.
Second, although scientific justification is always needed for
the choice of a trial design, justification for exposing people to
risks associated with placebo use must be more compelling as
the risk of not receiving treatment increases. However, what
this means in practice needs elucidation. Only when we
understand what reasons count as compelling reasons will
we be able to judge the ethics of placebo use in the most
controversial cases. The remainder of this analysis considers
how researchers and research ethics committees might
evaluate whether there are compelling methodological reasons
for placebo use.
4. Compelling methodological reasons
The relativemerits of different scientific designs are complex
and contextual. Experts may therefore disagree about the facts
underlying a claim that placebo use is scientifically required. In
the HIV perinatal trials, commentators disagreed about whether
or not active-controlled trials could reliably answer the relevant
scientific questions [12]. The investigators of an Indian placebo-
controlled trial of risperidone for the treatment of acute mania
[13] criticized for unnecessarily exposing participants to the
risks of non-treatment, [14] responded that a placebo groupwasnecessary “because patients with mania generally show a high
and variable placebo response, making it difficult to identify
their responses to an active medication” [15].
However, even when the facts are not disputed, deter-
mining whether there are sufficiently compelling methodo-
logical reasons for using placebo is not straightforward.
Sometimes a placebo control design is not strictly necessary
to answer a scientific question, but without it the knowledge
will be more difficult to obtain or less likely to result. For
example, active-controlled trials typically require more
participants for adequate power than PCTs. At what point
does the added difficulty of enrolling the needed number of
people constitute a compelling enough reason to justify a
PCT? In other cases, a different trial design might be expected
to yield some socially valuable knowledge, but not as much as
a PCT. For example, an equivalence trial might yield data
suggesting that a new intervention is comparable to an
established one within certain parameters, but the addition
of a placebo arm might provide additional information about
its relative effectiveness. In certain non-inferiority trials, it is
helpful to add a placebo arm for internal validity, for
example [16]. Would it be acceptable for a government to
fund a PCT to collect comparative or cost-effectiveness data
in order to make decisions about health care coverage?
The ethical requirement that there be compelling method-
ological reasons for using placebo is motivated by the concern
that participantsmight be unjustifiably exposed to the risk of no
treatment. Hence, to assess these reasons, both the risks of
placebo use and the social value of the knowledge that using
placebo is expected to provide must be assessed relative to
other possible trial designs. The importance of the additional
social value gained by using a placebo control must justify the
additional risks of using placebo. The following considerations
should be helpful in making these assessments (Table 2).
First, a judgment about whether methodological reasons
are sufficiently compelling depends on the study's social value,
not on strict scientific necessity. That a placebo-controlled
design is scientifically necessary to answer a particular
question is insufficient to justify the design. A study's goals
could always be re-described in a way that required the use of
placebo, e.g., the goal could be described as determining
whether an investigational drug is superior to placebo.
However, whether study goals, so described, justify putting
research participants at risk depends crucially on the social
value expected frommeeting those goals. It has been noted, for
example, that placebo-controlled trials of “me-too” drugs may
suffice to show they are safe and effective for approval by the
FDA, but do not give clinicians information they need to
understand the comparative clinical value of a drug [17]. The
right description of a study's goals for the purposes of ethical
analysis is one that links the scientific questions to the social
value of the generalizable knowledge that justifies carrying out
the research in the first place. Compelling methodological
reasons for using placebo must show how the use of placebo
allows realization of that social value in a way that other
designs would not.
Conversely, a placebo-controlled design might be justified
in some cases even if it were not scientifically necessary. For
example, the Bucharest Early Intervention Project (BEIP)
randomized abandoned children in Romanian institutions to
foster care or continued institutional care, even though the
Table 2
Evaluating compelling methodological reasons.
• The importance of the additional social value gained by using a placebo
control must justify the additional risks of using placebo.
• Three key points regarding methodological reasons:
o In order to justify placebo use, it is neither necessary nor sufficient
that a placebo control is scientifically required.
o In order to justify placebo use, it need not be impossible to attain the
study's goals using an alternative trial design.
o There are multiple sources of social value that can justify a PCT.
• These conclusions apply to all choices of trial design, not just
placebo-controlled trials.
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care was superior. The BEIP investigators established a foster
care program in Bucharest and their results were anticipated
by policy-makers who were interested in applying them in
Romania [18]. The tight connection forged between the project
and Romanian policy-makers suggests that this study had
sufficient social value to justify its design [19].
Social value is a fundamental, but under-analyzed, concept
in research ethics. Here, we interpret social value in a simple
way: social value comprises the benefits from the research,
including generalizable knowledge, for the sake of which it
is acceptable to ask people to take on risks and burdens.
Recommended benchmarks for ensuring social value include
defining who will benefit from the research and in what way
they will benefit [20]. So, for example, justifications for PCTs
in populations that lack access to existing treatments should
include the intention to develop interventions for those
populations—the social value and benefits from the research
should redound to people in the population from which
participants are drawn. For instance, when Discovery Labs
proposed conducting a placebo-controlled trial of a new
artificial surfactant for respiratory distress syndrome (RDS)
in Bolivia, one of the (several) criticisms of the proposed
study was that the company sought data in order to market
its drug in high-income countries, not to develop a product
that would help premature Bolivian infants with RDS [21].
Second, in order to justify the use of a placebo control it
does not need to be impossible to answer the socially
valuable question using another trial design. As noted, to be
powered to detect a particular effect size, a PCT requires
fewer participants than would an active controlled trial. In
certain studies, especially those for low prevalence dis-
eases, it might be possible, but unlikely, to enroll enough
participants to complete an active-controlled trial, or an
active-controlled trial might complete accrual only after
many years [22]. A placebo-controlled study might be able
to detect the treatment effect earlier and with fewer
participants. Mere possibility does not always tell us the
most sensible way to answer a socially valuable scientific
question.
Third, these examples indicate that there are different ways
in which one trial design may have greater social value than
another. Most often, a study will have social value because, as
designed, it will achieve its goals, such as determiningwhether
a new treatment is effective or changing health policy for the
better. Sometimes, a study as designedwill be expected to have
more social value than alternative designs because it is morelikely to achieve its goals. For example, the BEIP, as designed,
was thought to be more likely to influence Romanian policy
than other designs, though, of course, alternative studiesmight
have affectedpolicy and the PCTmightnot havehad the desired
effect. Alternatively, a study design may contribute to social
value because it has fewer opportunity costs than alternative
ways to achieve those goals. For example, if an alternative trial
design is more expensive than a PCT, then an opportunity cost
might be paid in not being able to use that money to conduct
other socially valuable research studies.
A cautionary note: achieving the goals of a study and having
lower opportunity costs are both potential sources of social
value. However, not all gains that result fromone's choice of trial
design count. To constitute social value they must be gains of a
type for which it is acceptable to ask people to take on risks or
burdens through research participation. We would judge, for
instance, that the advantage to a pharmaceutical company of
reducing costs by using placebo instead of an active control is
generally not the sort of advantage that should count. However,
a substantially greater probability that a PCT rather than an
active-controlled trial could enroll sufficient participants to
complete an important and timely study could be a relevant
consideration.
Finally, these considerations are not limited to the justifica-
tion of placebo-controlled trials. Researchers' choice of trial
design should always be justified whenever there is a choice
between different trial designswhich pose different levels of risk
and which are likely to differ in their contribution to the social
value of the research. PCTs are just the most controversial case.
5. Conclusions
Most commentators agree that placebo-controlled trials are
permissible in the four cases summarized in Table 1. A key issue
in the ethical justification of PCTs, especially for categories in
which non-treatment poses more than negligible risk, is what
counts as a compelling methodological reason supporting
placebo use. Here, we have argued that any additional risks of
using placebo must be justified by the additional social value
gained relative to other trial designs, and suggested some
important considerations for evaluating whether these reasons
are sufficiently compelling to justify a placebo-controlled design.
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